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Abstract
Background: The aim of this study was to examine the associations between 16 specific single nucleotide
polymorphisms (SNPs) in 8 obesity-related genes and overall and cause-specific mortality. We also examined the
associations between the SNPs and body mass index (BMI) and change in BMI over time.
Methods: Data were analyzed from 9,919 individuals who participated in two large community-based cohort
studies conducted in Washington County, Maryland in 1974 (CLUE I) and 1989 (CLUE II). DNA from blood
collected in 1989 was genotyped for 16 SNPs in 8 obesity-related genes: monoamine oxidase A (MAOA),
lipoprotein lipase (LPL), paraoxonase 1 and 2 (PON1 and PON2), leptin receptor (LEPR), tumor necrosis factor-α
(TNFα), and peroxisome proliferative activated receptor-γ and -δ (PPARG and PPARD). Data on height and weight
in 1989 (CLUE II baseline) and at age 21 were collected from participants at the time of blood collection. All
participants were followed from 1989 to the date of death or the end of follow-up in 2005. Cox proportional
hazards regression was used to obtain the relative risk (RR) estimates and 95% confidence intervals (CI) for each
SNP and mortality outcomes.
Results: The results showed no patterns of association for the selected SNPs and the all-cause and cause-specific
mortality outcomes, although statistically significant associations (p < 0.05) were observed between PPARG
rs4684847 and all-cause mortality (CC: reference; CT: RR 0.99, 95% CI 0.89, 1.11; TT: RR 0.60, 95% CI 0.39, 0.93)
and cancer-related mortality (CC: reference; CT: RR 1.01, 95% CI 0.82, 1.25; TT: RR 0.22, 95% CI 0.06, 0.90) and
TNFα rs1799964 and cancer-related mortality (TT: reference; CT: RR 1.23, 95% CI 1.03, 1.47; CC: RR 0.83, 95%
CI 0.54, 1.28). Additional analyses showed significant associations between SNPs in LEPR with BMI (rs1137101)
and change in BMI over time (rs1045895 and rs1137101).
Conclusion: Findings from this cohort study suggest that the selected SNPs are not associated with overall or
cause-specific death, although several LEPR SNPs may be related to BMI and BMI change over time.
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Background
Epidemiologic studies from large, population-based
cohorts have shown that obesity, defined by a body mass
index (BMI) of 30 kg/m2 or greater, is associated with an
increased risk of mortality [1-6]. The biological plausibil-
ity of this association is well established, as it is known
that excess body fat can lead to cardiovascular disease,
type 2 diabetes mellitus, and cancer [7].
Individual behaviors, such as physical activity and eating
habits, are known to play important roles in the develop-
ment of obesity [7]. However, it has been hypothesized,
and observed in some studies, that genetic factors may
also be involved. These genetic factors include single
nucleotide polymorphisms (SNPs) in genes that encode
proteins involved in biological processes influencing
body composition, including fat metabolism and adi-
pocyte differentiation (peroxisome proliferator activated
receptor γ (PPARG)) [8], hydrolyzation of triglycerides in
both chylomicrons and very-low density lipoproteins
(lipoprotein lipase (LPL)) [9], regulation of leptin, a pro-
tein involved in body weight regulation (leptin receptor
(LEPR)) [10], prevention of low-density lipoprotein oxi-
dation (paraoxonase 1 (PON1) and 2 (PON2)) [11], and
regulation of monoamine levels (monoamine oxidase A
(MAOA)) [12]. A recent review by Yang et al [13] reported
that there are over 400 studies examining SNPs in these
types of genes and obesity, with 22 of these genes found
to be associated with obesity in at least five studies
[13,14]. While these genes may be associated with obes-
ity, little is known as to whether these genes also influence
mortality.
We analyzed data from two community-based cohorts
named CLUE I and CLUE II, established in Washington
County, Maryland in 1974 and 1989, respectively, to
examine the associations between SNPs in obesity-related
genes and overall and cause-specific mortality. As a sec-
ondary aim, we also examined the associations between
the genetic polymorphisms and BMI and change in BMI
over time. For this study, genotyping was conducted on
DNA extracted from blood samples collected in 1989 for
16 SNPs in the following 8 genes: MAOA, LPL, PON1,
PON2,  LEPR,  PPARG, tumor necrosis factor-α ( TNFα),
and peroxisome proliferator activated receptor δ
(PPARD). These genes were part of a larger group of genes
that were chosen by study investigators prior to the start of
project funding in 1999; they were selected because the
metabolic processes they control were thought to be rele-
vant to carcinogenesis as well as other disease processes,
including death. SNPs within the selected genes were cho-
sen because the minor allele frequency was estimated to
be at least 5% among Caucasians and the polymorphisms
were either known to be functional or were likely to alter
function because they encoded for a nonsynonymous
amino acid change or were located within the 5' or 3'
untranslated region of the gene and thus could potentially
alter mRNA stability.
Methods
Study Population
In 1974 and 1989, two cohorts named CLUE I and CLUE
II, derived from the slogan Give us a CLUE to Cancer, were
established in Washington County, Maryland in order to
collect blood samples from as many individuals as possi-
ble for the prospective examination of factors involved in
the development of cancer and cardiovascular disease. In
addition to a blood sample donation at baseline for all
participants, data were obtained using an interviewer-
administered questionnaire on age, gender, marital status,
education, height and weight (CLUE II only), weight at
age 21, cigarette smoking, and medication and vitamin
supplement use within the 48 hours prior to blood dona-
tion. Blood pressure was also measured and, in 1989, total
cholesterol was assayed. For this analysis, BMI at age 21
and at CLUE II baseline was calculated based the informa-
tion on weight collected at each time point and height
reported at CLUE II baseline. Individuals who donated
blood to both CLUE I and CLUE II constitute the Odyssey
Cohort (N = 8,394) [15].
In addition to the Odyssey Cohort, a CLUE II subcohort
was developed for case-cohort studies that would be con-
ducted using the CLUE II cohort data. The subcohort was
identified by taking a 10% age-stratified, random sample
of CLUE II participants who donated a blood specimen in
1989 and were adult residents of Washington County,
Maryland. Of the 2,460 participants identified for the sub-
cohort, 807 were also in the Odyssey Cohort (i.e., they
had participated in both CLUE I and CLUE II as described
above). These two groups were combined for the current
analysis (n = 10,047).
Of the participants in the Odyssey Cohort and the CLUE
II subcohort, DNA was successfully extracted from the
buffy coat samples of 9,960 individuals (99%). DNA from
these participants was genotyped for polymorphisms in
genes controlling biological processes such as obesity that
have been associated with multiple diseases. For the study
presented in this manuscript, Odyssey and subcohort par-
ticipants who were missing data on all of the chosen SNPs
were excluded from the analysis (n = 41). This study was
approved by the Johns Hopkins Bloomberg School of
Public Health's Institutional Review Board.
Genotyping
SNPs in obesity-related genes analyzed in the present
study were chosen because the minor allele frequency was
estimated to be at least 5% among Caucasians and the
polymorphisms were either known to be functional orBMC Medical Genetics 2009, 10:103 http://www.biomedcentral.com/1471-2350/10/103
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were likely to alter function because they encoded for a
nonsynonymous amino acid change or were located
within the 5' or 3' untranslated region of the gene and
thus could potentially alter mRNA stability. Descriptions
and dbSNP identifiers of the polymorphisms in obesity-
related pathways selected are shown on Additional file 1.
DNA extracted from the preserved buffy coat samples col-
lected in 1989 were used for genotyping. Blood samples
were centrifuged at 1500 g for 30 minutes at room temper-
ature and were subsequently separated into plasma, buffy
coat, and red blood cells and frozen at -70°C within 24
hours of collection. The buffy coat remained frozen until
DNA extraction was performed. The DNA extraction pro-
cedures used the alkaline lysis method [16]. Following
DNA isolation, DNA samples were resuspended in 10 mM
Tris-HCl/1 mM EDTA (TE) and DNA concentration was
adjusted to 100 μg/mL. Genotyping was performed using
TaqMan technology by Celera Genomics Co. (Rockville,
MD) for the SNPs with rs numbers 1800629, 4684847,
709158, and 1175543. Genotyping was performed by
Applied Biosystems Inc. (Foster City, CA) for the SNPs
with rs numbers 1801291, 316, 662, 7493, 12026, 7602,
1045895, 1137101, 2016520, 1801282, 1799724, and
1799964. Laboratory technicians were masked to disease
status. The genotyping success rates of the selected poly-
morphisms ranged from 93% to 98%; 7,596 (76.6%) of
the individuals in the analytic dataset had data on all 16
SNPs.
Outcome assessment
All participants were followed from the date of blood
draw to the date of death or the end of follow-up (June 20,
2005), whichever came first. In the CLUE cohorts, deaths
are identified through daily searches of obituaries, cross-
linking with death certificates for Washington County and
through searches of the Social Security Administration
search for individuals aged 65 or older and the National
Death Index. Cause of death is ascertained from the
underlying cause on Maryland State death certificates as
coded by state nosologists. Of specific interest in this
study were cancer deaths, for which the underlying cause
was coded as ICD-9 140-239 or ICD-10 C00-C97, and car-
diovascular disease deaths, for which the underlying cause
was coded as ICD-9 390-459 or ICD-10 I00-I99. During
the follow-up period, 2,159 deaths were documented in
the Odyssey cohort and the CLUE II subcohort. Of these,
791 (36.6%) were cardiovascular deaths, 574 (26.6%)
were cancer deaths, and 775 (35.9%) were deaths due to
other causes.
Approximately 4% (n = 334) of the Odyssey cohort and
the CLUE II subcohort participants were lost to follow-up.
Since these individuals were not documented to have died
during the follow-up period, they were considered alive at
the end of follow-up and censored at June 20, 2005.
Statistical analysis
The Hardy-Weinberg equilibrium for each SNP was tested
using data from the entire study sample by a goodness-of-
fit approach using STATA version 9. Because the MAO
gene is linked to the X chromosome, Hardy-Weinberg
equilibrium for this gene was tested for women only.
Linkage disequilibrium was assessed using Haploview,
Version 3.2 (Cambridge, MA).
Multiple imputation [17] was used to account for missing
SNP data (range of missing data: 3 to 7%). Five independ-
ent complete datasets were constructed by predicting
missing genotypes with decision trees that employed all
variables relevant for the model building (other SNPs in
linkage disequilibrium, demographic variables/covariates
associated with the SNP, and the outcome). If no variables
were associated with the SNP (including the outcome),
imputation was based on the marginal distribution of the
SNP with the missing data. Relative risk (RR) estimates
were then obtained by combining estimates and standard
errors from analyzing the five complete datasets. Cox pro-
portional hazards regression was used to obtain the RR
and 95% confidence interval (95% CI) for each SNP and
mortality outcomes. For cause-specific death outcomes,
all competing deaths were treated as censored observa-
tions at time of death. Genetic variations were coded by
genotype with the reference category being the homozy-
gote of the major allele. The statistical significance of the
association between each genotype with respect to each
outcome was examined using a chi-square goodness of fit
test. All analyses were stratified by 10-year age groups to
allow for a different baseline hazard for each 10-year age
group; in addition, all RR estimates were age- and gender-
adjusted. Other variables considered for adjustment
included baseline BMI, change in BMI from age 21 to
baseline, education (less than 12, 12, greater than 12
years), cigarette smoking status (never, former, current),
systolic blood pressure, and diastolic blood pressure.
Because the RR estimates did not change after multivaria-
ble adjustment or by using the imputation methods, only
age- and gender-adjusted and stratified estimates using
the non-imputed data are presented.
SNP-SNP interactions for all single-locus markers were
examined using the imputed data by logic regression, an
adaptive regression approach based on Boolean combina-
tions of binary variables [18]. Each SNP was recorded in
two binary variables that described the genotype.
Specifically, one variable was created for the presence of
the dominant allele and one variable for the homozygote.
For SNPs with low minor allele frequencies, the heterozy-BMC Medical Genetics 2009, 10:103 http://www.biomedcentral.com/1471-2350/10/103
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gote and the less common homozygote were combined.
Using a logistic link with death being the outcome,
Boolean combinations of those binary predictors were
examined as new possible covariates, adjusting for age
and gender simultaneously. Permutation tests for model
selection were carried out described in Ruczinski et al
[19].
Further, to explore the potential for each SNP to be asso-
ciated with premature death (all cause or cause-specific),
Kaplan-Meier curves for the associations between each
SNP and the mortality outcomes were examined. There
were no indications that any of the three genotype curves
for each SNP diverged early in the follow-up time period
rather than later; therefore, it was decided that no further
analyses for premature death would be considered or dis-
played in the results.
Additional analyses were conducted to examine the asso-
ciations for the SNPs with baseline BMI and BMI change
from age 21 to baseline adjusted for age and gender. For
both analyses, the outcome variable was treated as a con-
tinuous outcome and analyzed with Normal regression.
An analysis was also conducted to examine the risk of hav-
ing a BMI ≥25 kg/m2 at baseline (newly "overweight")
associated with the investigated SNPs among those who
had a BMI <25 kg/m2 at age 21.
All analyses were performed using R version 2.6.0 (The R
Project for Statistical Computing, http://www.r-
project.org/) unless otherwise specified. A two-sided P
value of < 0.05 was considered statistically significant.
Results
Characteristics of the sample are shown on Table 1. The
mean age of participants at the time of blood draw was
53.1 years (standard deviation (SD) = 15.5); 99% of the
participants were of Caucasian race. Approximately 62%
of the sample was female and 16.5% were current smok-
ers. The mean BMI of participants at the time of blood
draw was 26.3 kg/m2 (SD = 4.9); 19.3% had a BMI of ≥30
kg/m2. About a quarter of the participants were taking
hypertension medications; 5.3% were taking medication
for elevated cholesterol.
All of the polymorphisms examined were in Hardy-Wein-
berg equilibrium. The following SNPs were in strong link-
age disequilibrium (D' > 90): PON2 Ser299Cys and PON2
Ala136Gly (D' = 99), LEPR rs7602 and LEPR rs1045895
(D' = 99), TNFα rs1799964 and TNFα rs1799724 (D' =
98), and PPARG rs709158 and PPARG rs1175543 (D' =
97).
In general, there were no observable patterns of associa-
tion for the selected SNPs and the all-cause and cause-spe-
cific mortality outcomes (see Additional file 2, Additional
file 3, and Additional file 4), although some individual
SNPs showed statistically significant associations. As
reported in a previous publication [20], the PPARG
rs4684847 genotype was significantly associated with all-
cause mortality, although, when stratified by gender, the
association was statistically significant only among males
(see Additional file 5, Additional file 6). Further, PPARG
rs4684847 was significantly associated with cancer-
related mortality; the decrease in risk associated with car-
rying two of the recessive alleles was observed among
females only, although this risk estimate in females was
not statistically significant. Additionally, TNFα
rs1799964 was significantly associated with cancer-
related mortality in the entire sample (p = 0.03); however,
these was no evidence of a dose-response trend between
number of variant alleles and the risk of cancer-related
death. There were no statistically significant associations
between the genotypes and cardiovascular-related mortal-
ity in the entire sample or among males and females sep-
arately. None of the associations reported above
materially changed after adjustment for BMI or BMI
Table 1: Characteristics of study sample at 1989 blood draw
Characteristic
N9 9 1 9
Mean age (years) and SD 53.1 (15.5)
Female (%) 61.5
Married (%) 73.0
Cigarette smoking status
Never (%) 53.9
Former (%) 29.6
Current (%) 16.5
Mean education (years) 12
Treatment for hypertension
Yes (%) 24.2
Mean systolic blood pressure (mmHg) 138.8
Mean diastolic blood pressure (mmHg) 82.7
No (%) 75.7
Mean systolic blood pressure (mmHg) 124.4
Mean diastolic blood pressure (mmHg) 78.0
Treatment for elevated cholesterol
Yes (%) 5.3
No (%) 94.7
Mean cholesterol (mg/dL) 208.8
Mean body mass index (kg/m2)2 6 . 3
Body mass index (kg/m2) by category
<25.0 (%) 42.9
25.0-29.9 (%) 37.8
≥30.0 (%) 19.3BMC Medical Genetics 2009, 10:103 http://www.biomedcentral.com/1471-2350/10/103
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change from age 21 to baseline, including the associations
reported above. When the joint effects of the SNPs were
considered, no statistically significant interactions were
observed: the likelihoods of the interrogated SNP-SNP
interactions could be explained by chance alone.
The associations for the selected SNPs with baseline BMI,
BMI change from age 21 to baseline, and BMI ≥25 kg/m2
at baseline among those with BMI <25 kg/m2 at age 21 are
reported on Table 2. The LEPR Gln223Arg SNP was signif-
icantly associated with BMI after adjustment for age and
gender (p = 0.02); however, there was no dose-response
relationship present between BMI and the number of var-
iant alleles. The LEPR rs1045895 and LEPR Gln223Arg
SNPs were significantly associated with change in BMI
from age 21 to baseline such that, for both SNPs, the
mean BMI change was significantly related to the number
of variant alleles (p < 0.05). Finally, the PPARG Pro12Ala
SNP was significantly associated with having a BMI ≥25
kg/m2 at baseline among individuals with a BMI <25 kg/
m2 at age 21. Specifically, individuals who were <25 kg/
m2 at age 21 and who carried the Ala/Ala genotype were
almost two times as likely to have a BMI ≥25 kg/m2 at
baseline compared to individuals who were <25 kg/m2 at
age 21 and carried the Pro/Pro genotype (OR = 1.91; 95%
CI 1.28, 2.88). These associations did not differ by gender.
There were no statistically significant associations
between the other selected SNPs and BMI or change in
BMI from age 21 to baseline among all participants or
among males and females separately.
Discussion
In this community-based cohort study, we examined the
associations between 16 SNPs in 8 obesity-related genes
and found no strong evidence that the selected SNPs were
associated with overall or cause-specific mortality. These
results are consistent with some, but not all, of the studies
that make up the small body of literature examining SNPs
and longevity. The most frequently studied SNP of those
selected in this study is the PON1 Gln192Arg SNP; the
reported findings for the association between this SNP
and survival appear to differ by population. For example,
the  PON1  192Arg allele was found to be significantly
more common in nonagenarians and/or centenarians ver-
sus centenarians offspring and controls in several studies
conducted in Italy [21-23] (samples size of 308 centenar-
ians and 579 controls in Bonafe et al [22] and 96 nonage-
narians/centenarians and 173 controls in Marchegiani et
al [23]), and was found to be associated with survival
among 1,932 Danish individuals aged 47 to 93 [24]. In
contrast, an association between this SNP and longevity
was not observed in a sample of 592 Irish men and
women [21], among American Caucasian long-living
individuals (n = 749) and young controls (n = 355) [25],
or in a cohort of 666 Danish subjects aged 85 years or
older [26]. PON1 has been shown to be involved in the
protection of LDL against lipid oxidation, and the func-
tionality of the PON1 Gln192Arg SNP has been demon-
strated, with the 192Gln/Gln genotype showing the most
protection and the 192Arg/Arg showing the least [27]. The
reasons for the inconsistent results regarding this SNP and
longevity are unclear; however, most studies have been of
small sample size, making the detection of weak associa-
tions difficult. Further, differing results may be the result
of differences in environmental exposures that may alter
expression of the genes in different populations [25,28].
This study also provided little evidence that the selected
SNPs are associated with body mass or change in BMI over
time, although the LEPR rs1045895 and LEPR Gln223Arg
SNPs were found to be significantly associated with BMI
change from age 21 to baseline. To our knowledge this is
the first study to report on such associations; however,
studies have examined the LEPR Gln223Arg SNP in rela-
tion to obesity and a recent meta-analysis showed no evi-
dence of an association between the LEPR Gln223Arg SNP
with the obesity outcome [29]. This report is not incon-
sistent with our results, as the LEPR Gln223Arg SNP was
not associated with BMI or with the mortality outcomes.
The LEPR rs1045895 SNP is in an intron region and was
not associated with mortality; however, it may be linked
to functional SNPs that play a role in a pathway leading to
a gain in BMI over an individual's lifetime.
As the prevalence of overweight and obesity rises, there
has been an increasing interest in the potential role of
genetics in the development of obesity. Recent results
from several genome wide association studies showed
that SNPs in the fat mass and obesity gene (FTO), a gene
not examined in this study, were associated with obesity
among both children and adults, stimulating interest in
the genetic origins of obesity [30-34]. Further, new find-
ings from a population of 362,200 Danish men suggest
that the minor A-allele in FTO rs9939609 is associated
with an increased risk of mortality, although, interest-
ingly, the association was observed independent of fat-
ness (i.e. BMI, fat mass, and fat-BMI) [35]. Other new
findings have shed light on a probable genetic origin of
obesity; these findings include those reported in studies
showing associations between BMI and/or other measures
of body composition and SNPs in the catenin, beta like 1
gene (CTNNBL1) [36], the melanocortin-4 receptor
(MC4R) [31,32,37-40] and the insulin-induced gene 2
(INSIG2) [36,41-43], among others. Additionally, SNPs
in the genes investigated in this study, other than those
measured, have been shown to be associated with obesity,
body mass, and other cardiovascular risk factors. For
example, in a study of 3,653 residents of Osaka, Japan,
researchers showed the LEPR Arg109Lys SNP was associ-
ated with obesity such that individuals with the 109Lys/BMC Medical Genetics 2009, 10:103 http://www.biomedcentral.com/1471-2350/10/103
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Table 2: Associations of obesity-related SNPs with BMI, change in BMI, and risk of becoming overweight
BMI (kg/m2) at baseline 
(1989)
BMI change from age 21 to 
baseline (1989)
BMI ≥25 kg/m2 at baseline (1989) among 
those with BMI <25 kg/m2 at age 21a
Gene rs # Difference in 
meanb
(95% CI)
p-value Difference in 
meanb
(95% CI)
p-value Odds ratiob
(95% CI)
p-value
PPARG 4684847 0.36 0.57 0.20
CC Reference Reference 1.00 (reference)
CT 0.18 (-0.07, 0.43) -0.07 (-0.30, 0.15) 1.06 (0.95, 1.20)
TT 0.17 (-0.67, 1.02) 0.30 (-0.45, 1.06) 1.35 (0.91, 2.01)
PPARG 709158 0.88 0.59 0.86
AA Reference Reference 1.00 (reference)
GA 0.05 (-0.16, 0.27) 0.09 (-0.10, 0.28) 0.97 (0.88, 1.07)
GG 0.02 (-0.29, 0.33) 0.11 (-0.17, 0.39) 0.99 (0.86, 1.14)
PPARG 1175543 0.99 0.52 0.79
AA Reference Reference 1.00 (reference)
AG -0.01 (-0.22, 0.20) 0.05 (-0.14, 0.24) 0.97 (0.88, 1.07)
GG -0.03 (-0.34, 0.29) 0.16 (-0.12, 0.44) 0.99 (0.85, 1.14)
PPARG 1801282 0.69 0.70 0.01
CC Reference Reference 1.00 (reference)
CG 0.09 (-0.16, 0.34) -0.02 (-0.24, 0.20) 1.03 (0.92, 1.16)
GG 0.23 (-0.6, 1.06) 0.31 (-0.44, 1.06) 1.91 (1.28, 2.88)
PPARD 2016520 0.61 0.40 0.54
TT Reference Reference 1.00 (reference)
CT -0.09 (-0.31, 0.12) -0.13 (-0.32, 0.06) 0.97 (0.88, 1.07)
CC 0.11 (-0.42, 0.64) -0.08 (-0.56, 0.39) 1.10 (0.86, 1.41)
LPL 316 0.39 0.55 0.78
CC Reference Reference 1.00 (reference)
AC 0.07 (-0.17, 0.31) 0.1 (-0.09, 0.29) 1.03 (0.94, 1.14)
AA 0.53 (-0.28, 1.34) 0.01 (-0.28, 0.30) 1.00 (0.86, 1.16)
PON1 662 0.61 0.59 0.75
TT Reference Reference 1.00 (reference)
CT -0.08 (-0.29, 0.12) 0.10 (-0.11, 0.32) 1.04 (0.93, 1.17)
CC -0.14 (-0.51, 0.22) -0.12 (-0.85, 0.60) 0.96 (0.65, 1.40)
LEPR 7602 0.47 0.71 0.34
GG Reference Reference 1.00 (reference)
AG -0.14 (-0.35, 0.08) -0.06 (-0.24, 0.13) 0.93 (0.85, 1.02)
AA -0.05 (-0.55, 0.45) 0.07 (-0.26, 0.39) 0.98 (0.83, 1.16)
LEPR 1045895 0.69 0.01 0.12
GG Reference Reference 1.00 (reference)
AG 0.08 (-0.14, 0.30) -0.28 (-0.47, -0.09) 0.93 (0.84, 1.03)
AA -0.02 (-0.31, 0.28) -0.30 (-0.75, 0.15) 1.16 (0.92, 1.48)
LEPR 1137101 0.02 0.04 0.39
AA Reference Reference 1.00 (reference)
AG -0.18 (-0.41, 0.05) 0.22 (0.03, 0.42) 1.07 (0.97, 1.19)
GG 0.18 (-0.11, 0.46) 0.26 (0.00, 0.53) 1.05 (0.92, 1.21)
PON2 7493 0.50 0.18 0.27
GG Reference Reference 1.00 (reference)
CG 0.02 (-0.19, 0.23) -0.17 (-0.38, 0.04) 0.94 (0.85, 1.05)
CC 0.27 (-0.18, 0.72) 0.00 (-0.26, 0.25) 1.03 (0.90, 1.18)
PON2 12026 0.59 0.64 0.05
CC Reference Reference 1.00 (reference)
CG 0.03 (-0.18, 0.24) 0.08 (-0.10, 0.27) 1.08 (0.98, 1.19)
GG 0.23 (-0.22, 0.68) 0.11 (-0.29, 0.51) 1.25 (1.02, 1.55)
TNFα 1800629 0.27 0.56 0.07
GG Reference Reference 1.00 (reference)
GA 0.15 (-0.07, 0.38) 0.09 (-0.09, 0.28) 1.08 (0.98, 1.19)
AA -0.22 (-0.82, 0.39) 0.13 (-0.27, 0.54) 1.23 (1.00, 1.51)
TNFα 1799724 0.19 0.19 0.06
CC Reference Reference 1.00 (reference)
CT -0.24 (-0.50, 0.02) 0.19 (-0.01, 0.38) 1.11 (1.00, 1.23)
TT 0.11 (-0.91, 1.13) 0.07 (-0.47, 0.62) 0.84 (0.63, 1.12)
TNFα 1799964 0.06 0.31 0.87BMC Medical Genetics 2009, 10:103 http://www.biomedcentral.com/1471-2350/10/103
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Lys genotype were at increased risk compared to those
with the 109Arg/Arg genotype [44]. Investigating the asso-
ciations between these SNPs and mortality would provide
additional insight in to the long-term health effects of car-
rying specific obesity-related genotypes.
Obesity is a major public health concern. In a recent
report, the International Obesity Taskforce estimated that,
worldwide, there are a total of 1.1 billion adults are over-
weight, including 320 million who are obese [45]. Pres-
ently, the evidence points more towards the need for
primary and secondary prevention efforts that include the
incorporation of better health habits, such as eating right
and exercising, and away from the identification of at-risk
individuals through genetic screening. However, future
research should focus on explore whole genome scanning
approaches to find clues for multiple pathway interac-
tions that may lead towards obesity and mortality.
Conclusion
Findings from this cohort study suggest that the selected
SNPs are not associated with overall or cause-specific
death, although several LEPR SNPs may be related to BMI
and BMI change over time. Focus should be primarily on
the incorporation of better health habits to prevent obes-
ity and not genetic screening.
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TT Reference Reference 1.00 (reference)
CT 0.22 (0.01, 0.43) -0.18 (-0.42, 0.06) 1.01 (0.89, 1.14)
CC -0.16 (-0.61, 0.29) 0.11 (-0.81, 1.03) 0.88 (0.55, 1.40)
MAOA (F) 1801291 0.45 0.30 0.82
CC Reference Reference 1.00 (reference)
CT 0.16 (-0.13, 0.45) 0.10 (-0.09, 0.29) 1.02 (0.93, 1.13)
TT -0.10 (-0.61, 0.42) -0.19 (-0.60, 0.21) 0.96 (0.78, 1.18)
MAOA (M) 1801291 NA NA NA
CC Reference Reference 1.00 (reference)
TT -0.07 (-0.36, 0.22) 0.08 (-0.17, 0.33) 1.02 (0.90, 1.15)
95% CI, 95% confidence interval; NA, not applicable
a n = 7970 with self-reported BMI < 25 kg/m2 at age 21
b Adjusted for age and gender
Table 2: Associations of obesity-related SNPs with BMI, change in BMI, and risk of becoming overweight (Continued)BMC Medical Genetics 2009, 10:103 http://www.biomedcentral.com/1471-2350/10/103
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